Welcome to our dedicated page for Koru Med Sys news (Ticker: KRMD), a resource for investors and traders seeking the latest updates and insights on Koru Med Sys stock.
KORU Medical Systems Inc (KRMD) specializes in innovative subcutaneous infusion systems for critical therapies. This hub provides authorized updates about the company's medical device developments, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely announcements including product launch details, financial disclosures, and manufacturing updates. Our curated collection ensures access to verified information about FREEDOM infusion systems and related technologies.
Key updates cover FDA clearances, partnership announcements, clinical application insights, and operational developments. All content maintains strict compliance with financial disclosure regulations and medical device reporting standards.
Bookmark this page for streamlined access to KRMD's latest advancements in immunoglobulin therapy delivery systems. Check regularly for official updates directly impacting the medical device sector and chronic care treatment landscapes.
KORU Medical Systems (NASDAQ: KRMD) reported strong Q2 2025 financial results, achieving a significant milestone with quarterly revenue exceeding $10.2 million, marking a 21% increase year-over-year. The company's core business revenue grew 19% to $9.3 million, while Pharma Services and Clinical Trials revenue surged 42% to $0.9 million.
Key highlights include gross profit of $6.5 million (63.5% margin), improved cash position with quarterly usage of $0.6 million, and the appointment of Adam Kalbermatten as Chief Commercial Officer. The company raised its 2025 revenue guidance to $39.5-$40.5 million, representing 18-20% growth, while maintaining gross margin guidance of 61-63%.
Notable developments include the Freedom Infusion System's expanded indication for Empaveli® in C3G and Primary IC-MPGN treatment, and a new FDA 510(k) submission for use with a rare disease biologic drug.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has granted inducement equity awards to its new Chief Commercial Officer, Adam Kalbermatten. The compensation package includes:
600,000 nonqualified stock options at $3.44 per share granted on August 1, 2025, and 300,000 restricted shares awarded on July 28, 2025. Both awards vest 25% annually over four years, with potential accelerated vesting. The Compensation Committee approved these awards under Nasdaq Listing Rule 5635(c)(4) as part of Kalbermatten's employment agreement dated June 30, 2025.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference.
The Company's management will deliver their presentation on August 13, 2025, at 10:30 am ET. Investors and interested parties can access both the live and archived webcast through the News/Events page in the Investors section of KORU Medical's website.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in subcutaneous infusion solutions, has scheduled its second quarter 2025 financial results announcement for August 6, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. U.S. and Canadian participants can dial (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's investor relations website for six months following the event.
KORU Medical Systems (NASDAQ: KRMD) has appointed Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Kalbermatten brings over 20 years of commercial leadership experience in medical devices and pharmaceuticals, joining from Becton Dickinson where he served as VP and GM of Advanced Drug Delivery Systems.
In his new role, Kalbermatten will oversee KORU Medical's global commercial strategy, including marketing, sales, market access, and pharmaceutical customer engagement. His previous experience includes serving as CEO of ZebraSci and holding global leadership positions at Terumo Medical Corporation. He holds engineering degrees from Stevens Institute of Technology and an MBA from Columbia Business School.
KORU Medical Systems (NASDAQ: KRMD) reported strong Q1 2025 financial results, with net revenues reaching $9.6 million, an 18% increase year-over-year. The company's core business grew 21% to $9.4 million, driven by domestic and international expansion. Gross profit increased 19% to $6.0 million, with improved margins of 62.8%.
Key highlights include plans to submit two FDA 510(k) clearances for commercialized drugs with the Freedom Infusion System™ in 2025. The company raised its 2025 revenue guidance to $38.5-39.5 million from $38.0-39.0 million, maintaining gross margin guidance of 61-63% and expecting positive cash flow from operations for 2025.
Despite a quarterly net loss and cash usage of $0.8 million, KORU ended Q1 with $8.7 million in cash. The company's growth was primarily driven by new patient starts, market share gains, and international geographical expansion.
KORU Medical Systems (NASDAQ: KRMD), a medical technology company specializing in large volume subcutaneous infusion solutions, has announced it will release its first quarter 2025 financial results on Wednesday, May 7, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. U.S. and Canadian participants can join via (877)-407-0784, while international callers should use (201)-689-8560. The webcast will be available on KORU Medical's website and archived for six months.
KORU Medical Systems (NASDAQ: KRMD) reported strong financial results for Q4 and full year 2024, with significant growth across all business segments. Q4 net revenues reached $8.8 million, up 23% year-over-year, while full-year revenues hit $33.6 million, an 18% increase.
The company's Core business saw Q4 revenues of $8.2 million (+19% YoY), while Novel Therapies revenue grew 122% to $0.7 million. Gross margin improved to 62.9% in Q4 and 63.4% for the full year. The company ended 2024 with $9.6 million in cash, achieving positive cash flow of $0.8 million in Q4.
For 2025, KORU Medical projects net revenues between $38.0-$39.0 million (13-16% growth), with gross margins of 61-63%. The company expects to be operational cash flow positive for full year 2025. Additionally, the Novel Therapies business will be renamed to Pharma Services and Clinical Trials (PST) starting Q1 2025.
KORU Medical Systems (NASDAQ: KRMD) has announced it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, where management will discuss financial results and provide a corporate update.
The conference call will be accessible via phone for U.S. and Canadian participants at (877)-407-0784, and international callers at (201)-689-8560. A live and archived webcast will be available on the company's investor relations website for six months.
FAQ
What is the current stock price of Koru Med Sys (KRMD)?
What is the market cap of Koru Med Sys (KRMD)?
